Aclaris Therapeutics, Inc.

LSE:0H8T Stock Report

Market Cap: US$265.3m

Aclaris Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

LSE:0H8T Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
19 Nov 24BuyUS$1,499,999Anand MehraIndividual666,666US$2.25
05 Aug 24BuyUS$472,757BML Capital Management, LLCCompany373,569US$1.29
31 Jul 24BuyUS$359,010BML Capital Management, LLCCompany273,730US$1.33
22 Jul 24BuyUS$201,808BML Capital Management, LLCCompany154,722US$1.33
05 Jul 24BuyUS$405,894BML Capital Management, LLCCompany352,397US$1.16
01 Jul 24BuyUS$1,742,075BML Capital Management, LLCCompany1,543,434US$1.15
18 Jun 24BuyUS$628,206BML Capital Management, LLCCompany545,000US$1.17
13 Jun 24BuyUS$1,781,897BML Capital Management, LLCCompany1,611,200US$1.15
04 Mar 24BuyUS$17,955Andrew Kenneth PowellIndividual14,500US$1.25

Insider Trading Volume

Insider Buying: 0H8T insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 0H8T?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders2,608,4672.44%
VC/PE Firms8,888,8888.31%
Hedge Funds21,011,86119.6%
Institutions35,242,98332.9%
General Public39,234,29836.7%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 51%.

Top Shareholders

Top 25 shareholders own 58.33% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
13.3%
BML Capital Management, LLC
14,250,000US$35.3m9.72%18.73%
8.31%
Vivo Capital, LLC
8,888,888US$22.0m0%1.87%
6.32%
Rock Springs Capital Management LP
6,761,861US$16.8m146%0.58%
4.38%
The Vanguard Group, Inc.
4,685,498US$11.6m-0.04%no data
3.15%
D. E. Shaw & Co., L.P.
3,371,849US$8.4m1.56%0.01%
2.81%
Millennium Management LLC
3,005,598US$7.5m-9.93%0.01%
2.3%
Stonepine Capital Management LLC
2,458,873US$6.1m27.6%2.17%
1.94%
Acadian Asset Management LLC
2,078,287US$5.2m8.61%0.01%
1.79%
Trium Capital Managers Ltd
1,912,990US$4.7m1.11%2.64%
1.6%
BlackRock, Inc.
1,711,797US$4.2m-15.8%no data
1.34%
Neal Walker
1,433,630US$3.6m5.19%no data
1.28%
Renaissance Technologies LLC
1,370,700US$3.4m48.6%no data
1.22%
Two Sigma Advisers, LP
1,301,500US$3.2m-9.42%0.01%
0.98%
Aldebaran Capital, LLC
1,043,152US$2.6m21.6%2.45%
0.9%
PEH Wertpapier AG
963,544US$2.4m0%0.17%
0.86%
Deutsche Asset & Wealth Management
923,313US$2.3m0%no data
0.86%
Jacobs Levy Equity Management Inc
915,509US$2.3m0%0.01%
0.85%
Two Sigma Investments, LP
907,916US$2.3m-18.4%0.01%
0.79%
Geode Capital Management, LLC
846,446US$2.1m9.34%no data
0.66%
Anand Mehra
710,030US$1.8m1,540%no data
0.65%
Samsara BioCapital LLC
696,171US$1.7m0%0.23%
0.54%
Acuitas Investments, LLC
578,139US$1.4m24.6%0.43%
0.53%
Palo Alto Investors LP
569,832US$1.4m0%0.2%
0.51%
FMR LLC
545,972US$1.4m-20.8%no data
0.45%
Morgan Stanley, Investment Banking and Brokerage Investments
477,557US$1.2m167%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 08:32
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aclaris Therapeutics, Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julian HarrisonBTIG
Louise ChenCantor Fitzgerald & Co.
Gavin Clark-GartnerEvercore ISI